Antibiotics and Immune Checkpoint Blockade in Patients With Cancer: First Do No Harm By Md Abdul Wadud Khan, PhD, Bertrand Routy, MD, PhD, Arielle Elkrief, MD, Jennifer A. Wargo, MDDecember 10, 2019 Despite the unprecedented improvement in clinical outcomes with the advent of immune checkpoint blockade for…
“Generative AI is poised to be a powerful ally for the global cancer care community…. Think of it as providing clinicians with an AI-powered assistant…
Waiting more than 42 days postdiagnosis to undergo surgery could increase the risk of cancer-related mortality among patients with certain breast cancer subtypes.
The disease we now call diffuse large B-cell lymphoma (DLBCL) has gone by the names of reticulum cell sarcoma, diffuse histiocytic lymphoma, and diffuse large…
In a phase II trial (PALMIRA) reported in the Journal of Clinical Oncology, Llombart-Cussac et al evaluated whether palbociclib rechallenge with second-line alternative endocrine therapy…
The National Comprehensive Cancer Network (NCCN) released its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, covering eight tumor types. Today,…
For postmenopausal women with HR-positive ductal carcinoma in situ (DCIS) treated with breast-conserving surgery, whole-breast irradiation, and adjuvant endocrine therapy, reexcision to achieve wider …
A study by researchers at the National Cancer Institute investigating cancer incidence in the United States between 2010 and 2019 has found that breast, colorectal,…
In the phase III KEYNOTE-689 trial, perioperative use of a PD-1 inhibitor given with standard therapy significantly improved event-free survival in newly diagnosed, previously untreated…
Today, the FDA granted accelerated approval to the combination of the dual RAF/MEK inhibitor avutometinib and the FAK inhibitor defactinib (Avmapki Fakzynja Co-pack) for adults…
In patients with aggressive gastroenteropancreatic neuroendocrine tumors, first-line treatment with the mTOR inhibitor everolimus and the somatostatin analog lanreotide more than doubled the median pr…
